{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:03:52Z","timestamp":1790748232634,"version":"4.1.0"},"reference-count":100,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Despite development of modern antiretrovirals with lower drug interaction potential than their predecessors, drug interaction challenges remain. Standard treatment regimens still require multiple antiretrovirals that may cause, or may be the target of, drug interactions. Additionally, people living with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> are living longer and often present with comorbid conditions that require concomitant long\u2010term drug therapy. Also, treatment of infectious diseases in resource\u2010limited settings can result in significant interactions. In this review, we describe absorption, distribution, metabolism, and excretion pathways as they relate to relevant drug interactions with antiretrovirals along with the potential clinical consequences of these interactions. We highlight clinical data that illustrate pertinent interactions and provide tools to assist in predicting drug interactions in the absence of clinical data. Given these tools and thoughtful consideration of drug combinations, drug therapy in people living with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> can be safely and effectively managed throughout their lifetime.<\/jats:p>","DOI":"10.1002\/cpt.1393","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T13:34:45Z","timestamp":1549805685000},"page":"1362-1377","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Contemporary Drug\u2013Drug Interactions in <scp>HIV<\/scp> Treatment"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-3725","authenticated-orcid":false,"given":"Aaron S.","family":"Devanathan","sequence":"first","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-6978","authenticated-orcid":false,"given":"Daijha J.C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie L.","family":"Cottrell","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Burgunder","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C.","family":"Saunders","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D.M.","family":"Kashuba","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy  Chapel Hill North Carolina USA"},{"name":"University of North Carolina School of Medicine  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"e_1_2_12_1_1","first-page":"44","article-title":"A brief history of antiretroviral therapy of HIV infection: success and challenges","volume":"47","author":"Palmisano L.","year":"2011","journal-title":"Ann. Ist. Super. Sanita."},{"key":"e_1_2_12_2_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","author":"DHHS","year":"2018"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1377610"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010611-134529"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw032"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-17"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70782-0"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit122"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181eb376b"},{"key":"e_1_2_12_10_1","unstructured":"Selzentry[package insert]. (Pfizer Inc. New York NY 2007)."},{"key":"e_1_2_12_11_1","unstructured":"Biktarvy[package insert]. (Gilead Sciences Inc. Foster City CA 2018)."},{"key":"e_1_2_12_12_1","unstructured":"Pifeltro[package insert]. (Merck & Co. Inc. Whitehouse Station NJ 2018)."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000219"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1081993"},{"key":"e_1_2_12_15_1","unstructured":"FDA.U.S. Food and Drug Administration birth control chart<https:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForWomen\/FreePublications\/ucm522453.htm> (2018). Accessed September 25 2018."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.07.10"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000692"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00036-X"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0204-8"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0452-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.08.018"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000033017.52484.81"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)01525-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069854"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00006-2"},{"key":"e_1_2_12_26_1","unstructured":"Cottrell M.et\u00a0al.Altered TDF\/FTC pharmacology in a transgender female cohort: implications for PrEP[Abstract TUPDX0106]. In AIDS2018 (July 23\u201327 2018)."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.13.1573"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000260956.61835.6d"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.08.039"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04781.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.09.025"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1724"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2008.03.016"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60604-8"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a3172"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-016-0330-z"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001756"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1540"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2017.01.004"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1394455"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0222-7"},{"key":"e_1_2_12_43_1","unstructured":"Liverpool U.O.HIV drug interactions \u2013 interaction checker<https:\/\/www.hiv-druginteractions.org\/checker> (2018). Accessed September 6 2018."},{"key":"e_1_2_12_44_1","unstructured":"Genvoya[package insert]. (Gilead Sciences Inc. Foster City CA 2015)."},{"key":"e_1_2_12_45_1","unstructured":"Prezista[package insert]. (Janssen Therapeutics. Titusville NJ 2006)."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31825c7f24"},{"key":"e_1_2_12_47_1","unstructured":"UpToDate.Heparin (unfractionated): drug Information<https:\/\/www.uptodate.com\/contents\/heparin-unfractionated-drug-information?search=heparin&source=search_result&selectedTitle=1=148&usage_type=default&display_rank=1> (2018). Accessed September 12 2018."},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014523115"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000630"},{"key":"e_1_2_12_50_1","unstructured":"Xarelto[package insert]. (Janssen Pharmaceuticals Inc. Titusville NJ 2011)."},{"key":"e_1_2_12_51_1","unstructured":"Brooks K.et\u00a0al.Cobicistat but not ritonavir increases dabigatran exposure. Conference on Retroviruses and Opportunistic Infections February 13\u201316 2017. Abstract 409."},{"key":"e_1_2_12_52_1","unstructured":"Onglyza[package insert]. (AstraZeneca Pharmaceuticals LP Wilmington DE 2009)."},{"key":"e_1_2_12_53_1","unstructured":"Tivicay[package insert]. (ViiV Healthcare Whitehouse Station NJ 2006)."},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1246180"},{"key":"e_1_2_12_55_1","unstructured":"CDC.Prescription opioid data: prescribing practices<https:\/\/www.cdc.gov\/drugoverdose\/data\/prescribing.html> (2017). Accessed September 18 2018."},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0968-1"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.13.18"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61050-2"},{"key":"e_1_2_12_59_1","unstructured":"National Comprehensive Cancer N.Cancer in people living with HIV<https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx> (2018)."},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.10"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-018-0626-9"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00001"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000071"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918818347"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052100"},{"key":"e_1_2_12_66_1","first-page":"805","article-title":"Use of a physiologically based pharmacokinetic model to simulate drug\u2010drug interactions between antineoplastic and antiretroviral drugs","volume":"72","author":"Molto J.","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.033"},{"key":"e_1_2_12_68_1","unstructured":"Kyprolis[package insert]. (Onyx Pharmaceuticals South San Francisco CA 2012)."},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"e_1_2_12_70_1","unstructured":"CDC.Epidemiology and prevention of HIV and viral hepatitis co\u2010infections<https:\/\/www.cdc.gov\/hepatitis\/populations\/hiv.htm> (2018). Accessed December 2 2018."},{"key":"e_1_2_12_71_1","unstructured":"AASLD\/IDSA.HCV guidance: Recommendations for testing managing and treating hepatitis C<https:\/\/www.hcvguidelines.org\/> (2018). Accessed September 24 2018."},{"key":"e_1_2_12_72_1","unstructured":"WHO.HIV and hepatitis coinfections<https:\/\/www.who.int\/hiv\/topics\/hepatitis\/en\/> (2017)."},{"key":"e_1_2_12_73_1","unstructured":"Zepatier[package insert]. (Merck & Co. Inc. Whitehouse Station NJ 2016)."},{"key":"e_1_2_12_74_1","unstructured":"Mavyret[package insert]. (Abbvie Inc. North Chicago IL 2017)."},{"key":"e_1_2_12_75_1","unstructured":"Epclusa[package insert]. (Gilead Sciences Inc. Foster City CA 2016)."},{"key":"e_1_2_12_76_1","unstructured":"Vosevi[package insert]. (Gilead Sciences Inc.Foster City CA 2017)."},{"key":"e_1_2_12_77_1","unstructured":"Harvoni[package insert]. (Gilead Sciences Inc.Foster City CA 2014)."},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky146"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.353"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1086\/432581"},{"key":"e_1_2_12_81_1","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"WHO","year":"2015"},{"key":"e_1_2_12_82_1","unstructured":"Baraclude[package insert]. (Bristol\u2010Myers Squibb Company Princeton NJ 2005)."},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0170-z"},{"key":"e_1_2_12_84_1","unstructured":"Tseng A.Antiretroviral interactions with transplant medications<www\u2010hivclinic\u2010ca\u2010main\u2010drugs_in\u20105a4c3915\u20108bfe\u2010409b\u20109983\u2010f73e662e709c.pdf> (Toronto General Hospital Immunodeficiency Clinic (https:\/\/hivclinic.ca\/main\/drugs_interact_files\/transplant-int.pdf)). Accessed September 24 2018."},{"key":"e_1_2_12_85_1","unstructured":"Prograf[package insert]. (Astellas Pharma Inc. Northbrook IL 1994)."},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200202150-00032"},{"key":"e_1_2_12_87_1","unstructured":"Neff G.et\u00a0al.Liver transplantation in HIV complex pharmacokinetic interactions between tacrolimus and highly active antiretroviral therapy. 4th International Workshop on Clinical Pharmacology of HIV Therapy March 27\u201329 2003. Abstract 8.4."},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1060372"},{"key":"e_1_2_12_89_1","unstructured":"CellCept[package insert]. (Genentech USA Inc. South San Francisco CA 1995)."},{"key":"e_1_2_12_90_1","unstructured":"WHO.Malaria in HIV\/AIDS patients<https:\/\/www.who.int\/malaria\/areas\/high_risk_groups\/hiv_aids_patients\/en\/> (2017). Accessed December 5 2018."},{"key":"e_1_2_12_91_1","unstructured":"CDC.Malaria treatment (United States)<https:\/\/www.cdc.gov\/malaria\/diagnosis_treatment\/treatment.html> (2017). Accessed December 5 2018."},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173509"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920011794520008"},{"key":"e_1_2_12_94_1","unstructured":"CDC.Treatment of LTBI and TB for persons with HIV<https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbhiv.htm> (2016). Accessed December 5 2018."},{"key":"e_1_2_12_95_1","first-page":"1","article-title":"Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47","author":"CDC","year":"1998","journal-title":"MMWR"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0068"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt446"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw220"},{"key":"e_1_2_12_99_1","unstructured":"German P. Pang P. West S. Han L.L. Sajwani K.&Mathias A.Drug interactions between direct acting anti\u2010HCV antivirals sofosbuvir\u00a0and ledipasvir and HIV antiretrovirals. 15th International Workshop\u00a0on Clinical Pharmacology of HIV and Hepatitis Therapy (2014)."},{"key":"e_1_2_12_100_1","unstructured":"Oberoi R.K.et\u00a0al.Interactions Between ABT\u2010493 plus ABT\u2010530 combination and rilpivirine or raltegravir. Conference on Retroviruses and Opportunistic Infections February 22\u201325 2016. Poster 453."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:29:49Z","timestamp":1699363789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1002\/cpt.1393"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1393","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"2018-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}